During the past decade, Norton Cancer Institute Research Program conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Norton Cancer Institute Research Program" are "Head and Neck Cancer" (1 trials), "Melanoma" (1 trials), "Metastatic Pancreatic Adenocarcinoma" (1 trials), "Non Small Cell Lung Cancer" (1 trials) and "Urethelial Carcinoma" (1 trials). Many other conditions were trialed in "Norton Cancer Institute Research Program" in a lesser frequency.

Most popular intervention types in "Norton Cancer Institute Research Program" are "Biological" (1 trials) and "Drug" (1 trials). Other intervention types were less common.

The name of intervention was led by "CO-1.01" (1 trials), "Enoblituzumab" (1 trials), "MGA012" (1 trials) and "Pembrolizumab" (1 trials). Other intervention names were less common.

The vast majority of trials in "Norton Cancer Institute Research Program" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Norton Cancer Institute Research Program". undefined are not yet recruiting, undefined are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Norton Cancer Institute Research Program, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Norton Cancer Institute Research Program, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 0 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".